Wellington Management Group LLP Increases Stock Position in Illumina, Inc. $ILMN

Wellington Management Group LLP increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 190.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,812,928 shares of the life sciences company's stock after purchasing an additional 1,188,004 shares during the period. Wellington Management Group LLP owned 1.20% of Illumina worth $318,767,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Fiduciary Financial Advisors purchased a new stake in Illumina during the second quarter worth $26,000. Keating Financial Advisory Services Inc. purchased a new stake in Illumina in the second quarter valued at about $32,000. Rakuten Securities Inc. purchased a new stake in Illumina in the second quarter valued at about $33,000. Elyxium Wealth LLC acquired a new stake in Illumina in the fourth quarter worth about $25,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina during the 4th quarter worth approximately $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 457,858 shares of the firm's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Patricia Leckman sold 783 shares of the business's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares of the company's stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,799,688 shares of company stock valued at $379,517,231. 2.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Guggenheim boosted their price target on Illumina from $200.00 to $226.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Evercore reaffirmed an "outperform" rating on shares of Illumina in a report on Monday, July 6th. Barclays boosted their target price on shares of Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a research note on Friday, July 31st. Leerink Partners increased their price target on shares of Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, July 17th. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $188.40.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $215.59 on Monday. The business's 50 day moving average price is $194.05 and its 200-day moving average price is $155.87. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81. The firm has a market capitalization of $32.55 billion, a price-to-earnings ratio of 40.22, a price-to-earnings-growth ratio of 3.03 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the firm earned $1.19 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source